NCT05663580Recruiting
Cohort Study of HIV-positive People, Treated With Long Acting Antiretroviral Therapy
Cohort Study of HIV-positive People, Treated With Long Acting Antiretroviral Therapy (SCohoLART)
Source: ClinicalTrials.gov · Last updated 19 Oct 2026
Brief summary (registry, in English)
Systematic, continuative collection of clinical and laboratory data on patients followed at lnfectious Diseases Unit of the IRCCS San Raffaele Hospital in Milan, receiving long-acting ART (Phase IV, single-center, prospective, cohort study) PRIMARY ENDOPOINT: Treatment failure over 48 weeks, defined as virological failure (VF) or therapy discontinuation for any reason (TD) SECONDARY ENDPOINTS: Clinical and pharmacological determinants of efficacy, tolerability, toxicity Modifications in risk and incidence of comorbidities Description of drug-resistance in case of VR Efficacy of rescue regimens in case of VF Quality of life and patient's satisfaction
- Status (registry)
- Recruiting
- Study type
- Observational
- Enrollment
- 1500 (estimated)
- First submitted
- 21 Nov 2022
- Start date
- 17 Jul 2022
- Primary completion date
- 17 Jul 2024
- Lead sponsor
- Castagna Antonella
- Diseases
- HIV
- NCT number
- NCT05663580
What you commit to
- Study type: Observational
- Planned participants: 1500
- From 17 Jul 2022 to the primary completion date, 17 Jul 2024
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- \- Any contraindication to the use of one or more long-acting drug, according to the technical sheet of the long-acting drug(s) planned to be started (including pregnancy, current or planned).
Who the study is looking for
- HIV infection;
- Age \> 18 years;
- HIV-RNA \<50 copies/ml;
- Stable ART;
- Planned start of a long-acting regimen approved by AIFA (initially, cabotegravir and rilpivirine);
- Written informed consent provided.
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Save your city in your profile to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Ospedale San Raffaele Scientific Institute Coordinator of this site? Confirm its status | Milan | Italy | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.